News Releases

Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

June 7, 2019 at 8:30 AM EDT

WARREN, N.J., June 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today announced that management will present at the JMP Securities Life Sciences Conference to be held in New York, NY on June 19-20 and at the BMO Prescription for Success Healthcare Conference to be held in New York, NY on June 25. Presentation times are as follows:

(PRNewsfoto/Aquestive Therapeutics)

JMP Securities Life Sciences Conference
Thursday, June 20th at 9:00 AM ET

BMO Prescription for Success Healthcare Conference
Tuesday, June 25th at 10:40 AM ET

A webcast of the presentation will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of each webcast will be available for 90 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively-administered standard of care therapies. The Company also collaborates with pharmaceutical partners to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458

Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-to-present-at-two-upcoming-investor-conferences-300863450.html

SOURCE Aquestive Therapeutics, Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds